Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock

WINDTREE THERAPEUTICS INC /DE/

Primary endpoint met: istaroxime significantly improved systolic blood pressure (SBP AUC) vs placebo (p=0.0070) in combined Part A/B analysis.
Istaroxime improved cardiac output by ~15%, reduced heart rate, and lowered pulmonary capillary wedge pressure (PCWP) vs placebo at multiple timepoints.
Renal function (eGFR) improved with istaroxime at 48 hours (p=0.0291); NYHA heart failure classification improved through 72 hours.
Serious adverse events were similar: 10.5% istaroxime vs 27.3% placebo; no increase in clinically significant arrythmias observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.